Chiasma Inc (CHMA) Stock Price, Quote, News and Overview
NASDAQ:CHMA - Nasdaq -
CHMA Quote, Performance and Key Statistics
3.76
-0.24 (-6%)
The current stock price of CHMA is 3.76 null. In the past month the price decreased by -13.56%. In the past year, price decreased by -21.5%.
CHMA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About CHMA
Company Profile
Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. The company is headquartered in Needham, Massachusetts and currently employs 85 full-time employees. The company went IPO on 2015-07-16. The firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The firm has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The firm is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The firm's TPE technology enhances the absorption through the intestinal wall of drugs. The firm also focuses on developing CH2 for Orphan indication.
Company Info
Chiasma Inc
140 Kendrick Street, Building C East
Needham MASSACHUSETTS 02494 US
CEO: Raj Kannan
Employees: 85
Company Website: http://www.chiasmapharma.com/
Phone: 16179285300.0
Chiasma Inc / CHMA FAQ
What is the stock price of Chiasma Inc today?
The current stock price of CHMA is 3.76 null. The price decreased by -6% in the last trading session.
What is the ticker symbol for Chiasma Inc stock?
The exchange symbol of Chiasma Inc is CHMA and it is listed on the Nasdaq exchange.
On which exchange is CHMA stock listed?
CHMA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Chiasma Inc stock?
4 analysts have analysed CHMA and the average price target is 9.28 null. This implies a price increase of 146.86% is expected in the next year compared to the current price of 3.76. Check the Chiasma Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Chiasma Inc worth?
Chiasma Inc (CHMA) has a market capitalization of 217.68M null. This makes CHMA a Micro Cap stock.
How many employees does Chiasma Inc have?
Chiasma Inc (CHMA) currently has 85 employees.
What are the support and resistance levels for Chiasma Inc (CHMA) stock?
Chiasma Inc (CHMA) has a resistance level at 4.18. Check the full technical report for a detailed analysis of CHMA support and resistance levels.
Is Chiasma Inc (CHMA) expected to grow?
The Revenue of Chiasma Inc (CHMA) is expected to grow by 1731.35% in the next year. Check the estimates tab for more information on the CHMA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Chiasma Inc (CHMA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CHMA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CHMA, evaluating the profitability, health, valuation and growth aspects
- Chiasma Inc (CHMA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Chiasma Inc (CHMA) Sales and EPS estimates to see what analysts future expectations are.
- Chiasma Inc (CHMA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Chiasma Inc (CHMA) Insider and Institutional Ownership to learn about the owners and their transactions.
- Chiasma Inc (CHMA) Stock Chart to make your own analysis
- Chiasma Inc (CHMA) Latest news and press-releases to stay up to date.
Does Chiasma Inc (CHMA) stock pay dividends?
CHMA does not pay a dividend.
When does Chiasma Inc (CHMA) report earnings?
Chiasma Inc (CHMA) will report earnings on 2022-03-03, after the market close.
What is the Price/Earnings (PE) ratio of Chiasma Inc (CHMA)?
Chiasma Inc (CHMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
CHMA Technical Analysis
CHMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CHMA. While CHMA seems to be doing ok healthwise, there are quite some concerns on its profitability.
CHMA Financial Highlights
Over the last trailing twelve months CHMA reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS decreased by -46.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -2968.35% | ||
| ROA | -56.38% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CHMA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CHMA. The Buy consensus is the average rating of analysts ratings from 4 analysts.
For the next year, analysts expect an EPS growth of 12.13% and a revenue growth 1731.35% for CHMA